Omar F. Khan is founder and chief scientist of Tiba Biotech, a company spun out from his research at the Massachusetts Institute of Technology. Omar is widely published on topics at the interface of materials and life science. His areas of expertise include molecularly-defined nucleic acid delivery systems, vaccination nanotechnology, biomaterials, tissue engineering, reactor design, scale-up and translational research models. While earning his BASc and PhD in Chemical Engineering at the University of Toronto, he received the Society of Chemical Industry Merit Award and G.W. Ross Dowkes Memorial Prize, and completed his Professional Experience Year at a petrochemical refinery. As Professor Michael V. Sefton’s graduate student, he studied the effect of implant surface chemistry on the foreign body response. He also created new technologies for the rapid, bottom-up assembly and scalable production of vascularized tissues. As a post-doctoral associate and research scientist at MIT, he worked with Robert Langer and Daniel Anderson. Omar created new materials for targeted RNA delivery in the body, and synthesized new angiogenesis-inducing biomedical polymers for transplantation therapies.
Currently, Omar’s focus is on deploying his synthetic, molecularly-defined nucleic acid delivery technologies to generate rapid-response programmable vaccines for infectious diseases and cancer. This technology is integral to Tiba Biotech’s RNA-centric products for human and animal health.
Omar spends his free time biking, swimming and travelling with his family.